(Q48227989)

9 February 2018

title

Soluble interleukin-1 receptor type II levels are elevated in cerebrospinal fluid in Alzheimer's disease patients. (English)

1 reference

9 February 2018

0 references

0 references

5

1 reference

9 February 2018

author name string

Garlind A

1

1 reference

9 February 2018

Brauner A

2

1 reference

9 February 2018

Höjeberg B

3

1 reference

9 February 2018

Basun H

4

1 reference

9 February 2018

language of work or name

English

0 references

publication date

1 April 1999

1 reference

9 February 2018

published in

Brain Research

1 reference

9 February 2018

volume

826

1 reference

9 February 2018

issue

1

1 reference

9 February 2018

page(s)

112-116

1 reference

9 February 2018

Immunochemical identification of the serine protease inhibitor alpha 1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2899%2901092-6

β-Amyloid stimulates glial cells in vitro to produce growth factors that accumulate in senile plaques in Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2899%2901092-6

Interleukin-6 and α-2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2899%2901092-6

Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2899%2901092-6

Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2899%2901092-6

Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2899%2901092-6

Reciprocal control of inflammatory cytokines, IL-1 and IL-6, and β-amyloid production in cultures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2899%2901092-6

Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2899%2901092-6

Immunoglobulins and complement factors in senile plaques. An immunoperoxidase study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2899%2901092-6

Kainic acid induced expression of interleukin-1 receptor antagonist mRNA in the rat brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2899%2901092-6

Expression of amyloid precursor protein mRNAs in endothelial, neuronal and glial cells: modulation by interleukin-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2899%2901092-6

β-AMYLOID FRAGMENT POTENTIATES IL-6 AND TNF-α SECRETION BY LPS IN ASTROCYTES BUT NOT IN MICROGLIA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2899%2901092-6

Amyloid beta peptide potentiates cytokine secretion by interleukin-1 beta-activated human astrocytoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2899%2901092-6

Interleukin 1 regulates synthesis of amyloid beta-protein precursor mRNA in human endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2899%2901092-6

Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2899%2901092-6

Interleukin-6 improves the survival of mesencephalic catecholaminergic and septal cholinergic neurons from postnatal, two-week-old rats in cultures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2899%2901092-6

Interleukin-6 is not altered in cerebrospinal fluid of first-degree relatives and patients with Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2899%2901092-6

Increased cerebrospinal fluid tau in patients with Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2899%2901092-6

Sickness behavior as a new target for drug development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2899%2901092-6

The interleukin-1 receptor antagonist (rhIL-1ra) protects against cerebral infarction in a rat model of hypoxia-ischemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2899%2901092-6

Relationship of interleukin-1 beta and beta 2-microglobulin with neuropeptides in cerebrospinal fluid of patients with dementia of the Alzheimer type.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2899%2901092-6

Activation of microglial cells by beta-amyloid protein and interferon-gamma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2899%2901092-6

Induction of interleukin-1 beta mRNA in rat brain after transient forebrain ischemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2899%2901092-6

Convulsants induce interleukin-1 beta messenger RNA in rat brain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2899%2901092-6

Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2899%2901092-6

Glial cytokines in Alzheimer's disease: review and pathogenic implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2899%2901092-6

Neuronal differentiation factors/cytokines and synaptic plasticity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2899%2901092-6

Alpha 1-antichymotrypsin and IL-1 beta are not increased in CSF or serum in Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2899%2901092-6

Inhibition of interleukin-1 responsiveness by type II receptor gene transfer: a surface "receptor" with anti-interleukin-1 function.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2899%2901092-6

Cytokine indices in Alzheimer's temporal cortex: no changes in mature IL-1 beta or IL-1RA but increases in the associated acute phase proteins IL-6, alpha 2-macroglobulin and C-reactive protein.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2899%2901092-6

In situ hybridization study of interleukin-1β mRNA induced by kainic acid in the rat brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2899%2901092-6

Decreased interleukin-6 level in the cerebrospinal fluid of patients with Alzheimer-type dementia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2899%2901092-6

Overexpression of interleukin-1 receptor antagonist in the mouse brain reduces ischemic brain injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2899%2901092-6

10.1016/S0006-8993(99)01092-6

7 January 2021

Identifiers

DOI

1 reference

9 February 2018

PubMed ID

10216202

1 reference

9 February 2018